click to show more information

click to hide/show information About your Search

20120925
20121003
Search Results 0 to 0 of about 1
to actually do something that will be good for patients and good for science going forward so this is the one thing that didn't make it. the other little thick that didn't make it is now the safe dosage act, passed in the last minute, by the senate, and that's awaiting the president's signature, but one of the things that's necessary in terms of the resources is that this has to be a global enterprise. one of the things that is happening globally is the leading pharmaceutical companies in the united states, in europe, in japan have banded together to work with interpol to ensure they have enough resources to go after the bad guys around the world, and we've just started that. i think we're going to kick that off here next month. we've been discussing this with interpol, and we think we have a good program to help country's specific enforcement agencies with the global respective of interpol. yes, it costs money. it is money well spent, but more importantly, it gets us the heart of the trust that patients have to have in our medicines. >> ralph, i know as we've worked on the partnership and bu
Search Results 0 to 0 of about 1